<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764972</url>
  </required_header>
  <id_info>
    <org_study_id>McG 0713</org_study_id>
    <nct_id>NCT00764972</nct_id>
  </id_info>
  <brief_title>Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase IB/II Trial of Combination of Vinorelbine With Sorafenib (BAY 43-9006) as First-Line Treatment in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IB/II trial of sorafenib, a new tyrosine kinase inhibition of multiple genes&#xD;
      that is active against renal cancer, plus vinorelbine, a chemotherapy agent active in breast&#xD;
      cancer.&#xD;
&#xD;
      The investigators are combining these 2 drugs in order to determine if the investigators can&#xD;
      increase the activity of vinorelbine in metastatic breast cancer patients.&#xD;
&#xD;
      Patients with measurable metastatic breast cancer without previous chemotherapy for&#xD;
      metastatic disease are eligible for the protocol. They will be treated with 2 different dose&#xD;
      levels of sorafenib in order to determine the most tolerable dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed complete response (CR) or partial response (PR), defined according to RECIST criteria, persisting 4 weeks after the initial documentation.</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib and Vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib and Vinorelbine</intervention_name>
    <description>vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);&#xD;
sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.</description>
    <arm_group_label>Sorafenib and Vinorelbine</arm_group_label>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women affected by histologically proven metastatic breast cancer.&#xD;
&#xD;
          -  Tumor not susceptible to therapy with trastuzumab, defined as FISH negative for HER-2&#xD;
             amplification or immunohistochemistry 0-1+ for HER-2 expression.&#xD;
&#xD;
          -  Female, age ≥ 18.&#xD;
&#xD;
          -  Documented measurable disease by appropriate radiologic imaging according to RECIST&#xD;
             criteria (see Appendix E). Lesions in previously irradiated areas are not considered&#xD;
             measurable disease, unless progression has been documented post-radiation.&#xD;
&#xD;
          -  ECOG performance status 0-1 (see Appendix B)&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Adequate bone marrow function, as indicated by:&#xD;
&#xD;
               -  Hemoglobin ≥ 90 g/L&#xD;
&#xD;
               -  Neutrophils ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 109/L&#xD;
&#xD;
          -  Adequate renal function, as indicated by serum creatinine ≤1.5 times the upper limit&#xD;
             of normal and/or Creatinine Clearance calculated as &gt;50% lower normal limit, or&#xD;
             estimated as ≥ 50 ml/min (Appendix C).&#xD;
&#xD;
          -  Adequate liver function, as indicated by:&#xD;
&#xD;
               -  bilirubin ≤ 1.5 times upper normal limit;&#xD;
&#xD;
               -  AST and ALT ≤ 2 times upper normal limit.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50% as measured by either multigated&#xD;
             acquisition (MUGA) scan or echocardiogram (ECHO).&#xD;
&#xD;
          -  No therapy for breast cancer in the 4 weeks preceding the therapy start.&#xD;
&#xD;
          -  Women of childbearing potential must be using adequate contraception and have a&#xD;
             negative pregnancy test at the time of enrollment.&#xD;
&#xD;
          -  Patient able to understand and give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with locally advanced breast cancer or stage IIIb only.&#xD;
&#xD;
          -  Presence of only non-measurable disease.&#xD;
&#xD;
          -  Previous (neo)adjuvant chemotherapy with vinorelbine.&#xD;
&#xD;
          -  Any previous anti-angiogenic therapy.&#xD;
&#xD;
          -  Any previous chemotherapy for metastatic breast cancer. Previous hormonal treatments&#xD;
             or radiotherapy for metastatic disease are allowed.&#xD;
&#xD;
          -  Radiotherapy, chemotherapy or hormonal therapy for breast cancer in the last 4 weeks&#xD;
             prior to starting the study treatment.&#xD;
&#xD;
          -  Major surgery within 4 weeks of first study treatment, or minor surgery (including&#xD;
             placement of an access device) within 7 days of therapy start.&#xD;
&#xD;
          -  Presence of life-threatening disease or central nervous system localizations.&#xD;
&#xD;
          -  Evidence of HER-2 positive breast cancer, defined as FISH-positive for amplification&#xD;
             or score 3+ by immunohistochemistry.&#xD;
&#xD;
          -  Any other possibly active primary tumor, except basal cell carcinoma of the skin, or&#xD;
             carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Clinically significant hepatic disease with respect to hepatitis B, hepatitis C,&#xD;
             cirrhosis or other liver diseases.&#xD;
&#xD;
          -  Uncontrolled bacterial, viral or fungal infection.&#xD;
&#xD;
          -  Previous history of ischemic disease.&#xD;
&#xD;
          -  Patients with previous history of thrombo-embolic events, or with documented risk&#xD;
             factors for thrombotic disease other than cancer.&#xD;
&#xD;
          -  History of gross hemorrhage within the past 6 months (e.g., hemoptysis or hematuria&#xD;
             requiring medical intervention).&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Other serious medical conditions, such as uncontrolled cardiac disease, severe&#xD;
             pulmonary disease, uncontrolled diabetes.&#xD;
&#xD;
          -  Patient exhibiting confusion or disorientation.&#xD;
&#xD;
          -  Any condition (medical, social, psychological, geographical) that would prevent&#xD;
             adequate follow-up.&#xD;
&#xD;
          -  Patient is pregnant, or is breast-feeding, or is unwilling to use adequate&#xD;
             contraception.&#xD;
&#xD;
          -  Failure to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Panasci</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lawrence Panasci</last_name>
    <phone>514-340-8248</phone>
    <email>lpanasci@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristiano Ferrario</last_name>
    <phone>514-340-8248</phone>
    <email>cristianoferrario@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Panasci</last_name>
      <phone>514-340-8248</phone>
      <email>lpanasci@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Cristiano Ferrario</last_name>
      <phone>514-340-8248</phone>
      <email>cristianoferrario@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Panasci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>October 17, 2008</last_update_submitted>
  <last_update_submitted_qc>October 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cristina Attard, BSc Oncology Project Specialist</name_title>
    <organization>Bayer HealthCare Pharmaceuticals</organization>
  </responsible_party>
  <keyword>To evaluate the use of sorafenib added to vinorelbine chemotherapy, to find out which are the doses of two drugs can be safely combined</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

